Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections
Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections
复制标题
DOI：
10.1128/jvi.72.10.7852-7859.1998
复制
发表时间：
1998-10-01
影响因子：
5.4
通讯作者：
Montelaro, RC
中科院分区：
文献类型：
--
作者：
Cole, KS;Murphey-Corb, M;Montelaro, RC
对人类免疫缺陷病毒1型（HIV-1）和猿猴免疫缺陷病毒（SIV）的病毒特异性免疫应答的表征对于理解可能决定病毒感染和疾病过程的早期病毒-宿主相互作用是重要的。使用一个全面的面板的血清学检测，我们以前已经证明了一个复杂的和漫长的成熟的病毒特异性抗体反应引起的减毒株的SIV，这是密切相关的保护性免疫的发展。在本研究中，我们扩展了这些分析，以解决有关致病性SIV，SIV/HIV-1（SHIV）和HIV-1感染的病毒特异性抗体反应的性质的几个问题。结果首次证明了SIV，SHIV和HIV-1感染的抗体成熟的共同主题，其特征在于病毒感染后前6至10个月内抗体滴度，构象依赖性和抗体亲合力的持续变化。我们证明，这种病毒特异性抗体反应的逐渐演变是独立的病毒复制水平和感染病毒株的致病性。虽然这些研究中使用的血清学试验在评价减毒SIV疫苗效力期间可用于区分保护性和非保护性抗体应答，但这些相同的试验不能区分致病性SIV、SHIV或HIV-1感染的感染临床结局。这些结果可能反映了与控制已建立的病毒感染的免疫机制相比，参与介导病毒攻击保护的免疫机制的差异，并且它们表明体液和细胞反应的其他特征在这种早期免疫成熟过程中演变。
Characterization of virus-specific immune responses to human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) is important to understanding the early virus-host interactions that may determine the course of virus infection and disease. Using a comprehensive panel of serological assays, we have previously demonstrated a complex and lengthy maturation of virus-specific antibody responses elicited by attenuated strains of SIV that was closely associated with the development of protective immunity. In the present study, we expand these analyses to address several questions regarding the nature of the virus-specific antibody responses to pathogenic SIV, SIV/HIV-1 (SHIV), and HIV-1 infections. The results demonstrate for the first time a common theme of antibody maturation to SIV, SHIV, and HIV-1 infections that is characterized by ongoing changes in antibody titer, conformational dependence, and antibody avidity during the first 6 to 10 months following virus infection. We demonstrate that this gradual evolution of virus-specific antibody responses is independent of the levels of virus replication and the pathogenicity of the infection viral strain. While the serological assays used in these studies were useful in discriminating between protective and nonprotective antibody responses during evaluation of vaccine efficacy with attenuated SIV, these same assays do not distinguish the clinical outcome of infection in pathogenic SIV, SHIV, or HIV-1 infections. These results likely reflect differences in the immune mechanisms involved in mediating protection from virus challenge compared to those that control an established viral infection, and they suggest that additional characteristics of both humoral and cellular responses evolve during this early immune maturation.